2026-11-18. The following slide deck was published by Amylyx Pharmaceuticals, Inc.
2026-11-15. The following slide deck was published by Amylyx Pharmaceuticals, Inc.
Amylyx Pharmaceuticals has delivered a very strong year to date share price gain. With that kind of move on the board, the key issue for you now is whether the stock price still lines up with the company’s book value. A year to date return of 158.3% puts real pressure on the question of whether Amylyx’s current market value is still grounded in its underlying net assets. Positive Phase 3 LUCIDITY trial results for avexitide and a cash balance reported at US$768.1m after a recent equity raise...
Amylyx Pharmaceuticals Inc (AMLX) enters Q3 2026 with a strengthened balance sheet and a clear regulatory path toward a potential 2027 launch of avexitide for post-bariatric hypoglycemia.
Amylyx Pharma (NASDAQ:AMLX) held its second-quarter earnings conference call on Thursday. Below is the complete transcript from the call. This transcript is brought to you by Benzinga APIs. For real-time access to our
The Federal Reserve just lifted interest rates again to tackle stubborn inflation, which puts real pressure on weaker balance sheets and slow growing businesses. In this environment, investors may focus on companies that analysts expect to grow earnings solidly while keeping finances in reasonable shape. This article breaks down three such high potential US stocks from our quality growth list, explaining what sets each apart and where the key risks sit. The stocks covered below are just a...
Amylyx Pharmaceuticals (NASDAQ:AMLX) said its Phase III trial of avexitide in post-bariatric hypoglycemia, or PBH, met its primary endpoint and all secondary endpoints, positioning the company to submit a New Drug Application to the U.S. Food and Drug Administration before year-end. PBH is a chroni
CAMBRIDGE, Mass., September 23, 2026--Amylyx Pharmaceuticals to Present at the Stifel 2026 Virtual Cardiometabolic Forum
CAMBRIDGE, Mass., September 08, 2026--Amylyx Pharmaceuticals to Present at the 24th Annual Morgan Stanley Global Healthcare Conference
Eli Lilly is currently leading the GLP-1 market, but Amylyx is seeing strong results from its GLP-1 drug candidate.
Detailed price information for Amylyx Pharmaceuticals Inc (AMLX-Q) from The Globe and Mail including charting and trades.
The biotech delivered excellent news from the laboratory.
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) has released topline results from the Phase 3 LUCIDITY trial of avexitide on August 18, 2026. Shares closed Monday down 0.9% at $21.43, then traded 15.7% higher at $24.80 after hours after the company scheduled the readout. The rally came before investors saw any efficacy or safety data, underscoring how much […]
This is the newest page. Registered accounts read further back.